Welcome to our dedicated page for Dror Ortho-Design SEC filings (Ticker: DROR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dror Ortho-Design, Inc. (DROR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, offering insight into its orthodontic platform business and capital structure. As an AI-based orthodontic company developing the ZSmile smart aligner system, Dror uses SEC reports to describe its financing arrangements, reporting status, and registration activities.
Investors can review Current Reports on Form 8-K in which Dror details private placements of debentures and related warrants. These filings explain the principal amounts, maturity dates, conversion features tied to potential public offerings, and limitations on ownership percentages. They also describe the exemptions from registration under the Securities Act of 1933 that the company relies on for these transactions.
The filings page may also include registration statements such as Form S-1 and associated prospectus references, where Dror outlines the securities registered and background information about its AI-based orthodontic platform and ZSmile technology. Notifications of late filing, such as Form 12b-25 (NT 10-Q), provide context when the company requires additional time to complete and finalize its financial statements.
Through Stock Titan, users can access these DROR filings alongside AI-powered summaries that highlight key terms, structural features of debentures and warrants, and important dates. This helps readers quickly understand how Dror funds the development and commercialization of its ZSmile platform, how its reporting obligations are being met, and what regulatory steps it has taken in the U.S. capital markets.
Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement of Debentures with an aggregate principal amount of
Subject to completion of a public offering, investors are also entitled to receive Warrants to buy common stock at the public offering price, expiring five years from issuance, with customary anti-dilution and price-based adjustments. Both the Debentures and any Warrants include a 9.99% beneficial ownership cap, limiting how much equity any holder can acquire through conversion or exercise. The transaction was conducted as an unregistered offering under Section 4(a)(2) and Regulation D, with all purchasers represented as accredited investors.
Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement of 0% debentures with an aggregate principal amount of
Subject to the completion of that public offering, investors are also entitled to warrants for additional common shares, with quantities tied to the number of debenture conversion shares and a defined “warrant subscription amount.” Any warrants issued will be immediately exercisable at the public offering price and will expire five years after issuance. Both debenture conversions and warrant exercises are capped so that a holder cannot beneficially own more than
Dror Ortho-Design, Inc., a pre-revenue Israeli orthodontic device developer, reported a net loss of
Cash fell to
During the first nine months of 2025 Dror raised
Dror Ortho-Design, Inc. has filed a Form 12b-25 to notify the SEC and investors that its Quarterly Report on Form 10-Q for the nine months ended September 30, 2025 will be filed late. The company states it cannot meet the original deadline without unreasonable effort and expense because it needs more time to complete and finalize the financial statements required in the report.
The company indicates that it currently anticipates filing the Form 10-Q on or before the fifth calendar day following the prescribed due date, consistent with the timing relief available under Rule 12b-25 for quarterly reports.